FAM83B mediates EGFR- and RAS-driven oncogenic transformation

Journal of Clinical Investigation

Volumn 122, Issue 9, 2012, Pages 3197-3210

  Cipriano, Rocky ^a   Graham, James ^a   Miskimen, Kristy L S ^a   Bryson, Benjamin L ^a   Bruntz, Ronald C ^b   Scott, Sarah A ^b   Brown, H Alex ^b   Stark, George R ^a,c,d   Jackson, Mark W ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAM83B PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; EXON; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALIGNANT TRANSFORMATION; MUTAGENESIS; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VALIDATION BASED INSERTIONAL MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMARY GLANDS, HUMAN; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-RAF; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84865974367     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60517     Document Type: Article

References (27)

1. Lu T, et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A. 2009;106(38):16339-16344.
2. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res. 2007;67(20):9862-9868. (Pubitemid 47621234)
3. Cheng AS, et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 2008;68(6):1786-1796. (Pubitemid 351416564)
4. Novak P, et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 2006;66(22):10664-10670. (Pubitemid 44876960)
5. Xie Z, Ho WT, Exton JH. Association of N- and C-terminal domains of phospholipase D is required for catalytic activity. J Biol Chem. 1998;273(52):34679-34682. (Pubitemid 29028154)
6. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003;1(11):789-800. (Pubitemid 37174450)
7. Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007;258(2):268-275. (Pubitemid 350101020)
8. Brown HA, Henage LG, Preininger AM, Xiang Y, Exton JH. Biochemical analysis of phospholipase D. Methods Enzymol. 2007;434:49-87.
9. Lee S-Y, et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest. 2012;122(9):3211-3220.
10. Carracedo A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-3074.
11. Molzan M, et al. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol. 2010;30(19):4698-4711.
12. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875-885. (Pubitemid 39486539)
13. Kyriakis JM, et al. Raf-1 activates MAP kinasekinase. Nature. 1992;358(6385):417-421.
14. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121(2):179-193. (Pubitemid 40546387)
15. Zhang XF, et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature. 1993;364(6435):308-313.
16. Westbrook TF, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005;121(6):837-848. (Pubitemid 40806416)
17. Li Y, et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia. 2005;7(12):1073-1080. (Pubitemid 44430986)
18. Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer. 1991;27(8):977-980.
19. Mundhenke C, Strauss A, Schem C. Significance of tyrosine kinase inhibitors in the treatment of metastatic breast cancer. Breast Care (Basel). 2009;4(6):373-378.
20. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22. (Pubitemid 37328883)
21. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009;5(2):108-117.
22. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006;66(6):3169-3176.
23. Cipriano R, Patton JT, Mayo LD, Jackson MW. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis. Cell Cycle. 2010;9(7):1373-1379.
24. Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M, Jackson MW. TGF-{beta} signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2011;108(21):8668-8673.
25. Elenbaas B, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001;15(1):50-65. (Pubitemid 32060682)
26. Jackson MW, Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol. 2000;20(3):1001-1007. (Pubitemid 30044237)
27. Jackson MW, et al. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene. 2004;23(25):4477-4487. (Pubitemid 38850426)